GB2066259A - Antibody serum - Google Patents
Antibody serum Download PDFInfo
- Publication number
- GB2066259A GB2066259A GB8023481A GB8023481A GB2066259A GB 2066259 A GB2066259 A GB 2066259A GB 8023481 A GB8023481 A GB 8023481A GB 8023481 A GB8023481 A GB 8023481A GB 2066259 A GB2066259 A GB 2066259A
- Authority
- GB
- United Kingdom
- Prior art keywords
- solution
- igg
- serum
- reducing
- igm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 29
- 239000000427 antigen Substances 0.000 claims abstract description 31
- 102000036639 antigens Human genes 0.000 claims abstract description 31
- 108091007433 antigens Proteins 0.000 claims abstract description 31
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 19
- 230000004520 agglutination Effects 0.000 claims abstract description 16
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 9
- 230000002829 reductive effect Effects 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 29
- 239000003638 chemical reducing agent Substances 0.000 claims description 13
- 238000000502 dialysis Methods 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 8
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical group OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical group OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 claims description 3
- 238000010405 reoxidation reaction Methods 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960003151 mercaptamine Drugs 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 7
- 230000002269 spontaneous effect Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000004523 agglutinating effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 108091005588 alkylated proteins Proteins 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Blood grouping serum containing antibodies specific to human blood antigens and capable of direct agglutination of red blood cells without enhancing the spontaneous agglutination of immunoglobulin- coated cells, are produced by treating whole serum or a fraction containing IgG antibodies, separating IgM and IgG, reducing and thereby breaking disulfide bonds in the IgG, fixing the reduced IgG to prevent re-oxidation, and recombining with IgG.
Description
SPECIFICATION
Antibody serum
Over three hundred different blood group antigens have been identified in human blood.
Not all of these antigens appear in the blood of most humans. However, depending upon a number of factors, some known but many unknown, a combination of such antigens will be found in the blood of every individual.
Accordingly, when the blood of one individual is introduced into the circulation of another, as by a transfusion or pregnancy, chances are that the blood of the donor will contain one or more of the antigens not present on the red cells of the recipient. If this occurs, the immune mechanisms of the recipient may respond to the presence of these foreign antigens by producing antibodies in the recipient.
Depending upon the number and characteristics of the specific antigens involved, the presence of these antibodies in the blood serum of the recipient will produce effects which may be serious and which must be monitored and otherwise taken into account in subsequent transfusion or pregnancies.
To avoid or, at least, to minimize a potentially detrimental immune response, systems and procedures have been developed for typing blood and for matching donor and recipient bloods before transfusion. Laboratory identification of the most clinically significant antigens on the red cells of blood is typically carried out through the use of commercially available "anti-serums", i.e., blood serums containing known antibodies. The presence of each of the relevant antigens is determined by testing the red cells of the blood to be typed with the required anti-serum by specific test methods. Agglutination of the red blood cells being tested constitutes a positive test and indicates that the antigen corresponding to the anti-serum used is present, while no agglutination constitutes a negative test and indicates that the corresponding antigen is not present.Agglutination takes place through the linkage of the red blood cells as a result of the antibody in the anti-serum combining with antigens on two or more blood cells.
Antibodies are characterized as being "complete" or "incomplete", depending upon whether or not they have the characteristic of producing agglutination of the red blood cells in saline suspension. Antibodies specific to a particular antigen may occur in both forms, usually in varying proportions, depending upon the individual. There is no presently known way to predict, before an individual is exposed to a particular antigen, whether and to what extent the antibodies produced by that individual in response to the antigen will produce agglutination. Typically, more- "incomplete" than "complete" antibody will be generated.Commercial suppliers of specific anti-serums may pool the antibody serum from several different donors in order to produce an anti-serum having a suitable agglutinating quality (determined by a combined consideration of avidity, i.e. binding activity of that specific antibody, and titer, i.e., potency).
Antibodies have been further defined by classifying them according to the nature of the immunoglobulin protein molecule which makes up the antibody, the IgM molecule being that which comprises the naturally "complete" antibody, and the IgG molecule comprising the "incomplete" antibody. It is generally thought that the two immunoglobulin molecules are made up of similar basic polypeptides, the significant difference being that, unlike IgM, the IgG molecule is not large enough to produce a connecting bridge between antigen-bearing red blood cells in saline suspension. Thus, anti-serums manufactured from IgG antibodies require dilution in a high protein solution containing macromolecular additives, which makes them prone to false positive agglutination in certain situations, as will be described.
Further investigation has confirmed that the
IgG molecules are actually made up of four polypeptide chains, a pair of so-called "light" chains and a pair of "heavy" chains, held together as a molecular unit by disulfide bonds and by non-covalent interactions, as depicted in Fig. 1 of the drawings. It is on the two "Fab" portions of the molecules that the specific antigen binding sites appear, while the "Fc" portion contains no antigen binding sites. It is also thought that whereas the two antigen binding portions of the IgG molecule are separate from each other (being connected only by the disulfide linkage which joins the two chains), the Fc are connected to each other at a second point, represented in Fig. 1 as the line 2-2'.
It has been postulated and shown in the prior art that, under certain reducing conditions, the disulfide linkage joining the polypeptide chains may be broken without appreciably affecting intrachain disulfide linkages and the non-covalent interactions between the fragments comprising the Fc portion. Under such conditions, and with reference to Fig. 2 of the drawings, it is believed that the two
Fab portions thereupon move apart, while the fragments of the Fc portion remain joined at line 2-2'. It is thought that the molecule thus attains a span between the two antigen binding sites that is long enough such that an inter-cellular bridge is formed. The formation of these inter-cellular bridges overcomes the mutually repellent forces between the red cells in saline suspension and agglutination is able to occur.Thus, the modified IgG molecule so produced functions, in effect, as a "complete" antibody.
In the drawings:
Figure 1 is a representation of the physical structure of an IgG molecule as it exists naturally. The representation is intended to illustrate the different character of distinct portions of the polypeptide chains making up the molecule and how those chains are linked together.
Figure 2 is a representation of the same IgG molecule illustrated in Fig. 1, but after it has been subjected to reducing treatment.
According to the invention, blood serum containing antibodies specific to a particular human blood group antigen is first treated to remove and retain any IgM antibody, leaving a solution containing oniy IgG antibody. This solution is thereafter submitted to mild reducing conditions sufficient to split the disulfide bond linking the polypeptide chains of the IgG molecule while at the same time not sufficient to significantly reduce other portions of the molecule. This reaction is readily reversible due to reoxidation. Accordingly, the modified molecule must be "fixed" to substantially prevent reoxidation. This may be conveniently carried out by treating the solution containing the modified molecule with an alkylating agent, such as iodoacetic acid or iodoacetamide.In practice, any compound capable of reacting with the sulfhydril groups produced by the reduction process and which is not itself oxidized under any of the conditions to which the modified protein molecule may be submitted subsequently during the processing and/or storage procedures will be acceptable.
Following the fixing step, any reducing and fixing agents are removed from the solution containing the modified IgG molecule, by any appropriate method known to the art, and the solution is thereafter combined with that IgM fraction which was previously removed and retained. The total protein and salinity are adjusted to assure that the antibody serum will be of appropriate avidity and potency.
It will be apparent to those skilled in this art that the critical procedure in the method outlined above will be the actual reducing step.
The term "mild reducing conditions" is intended to refer to any conditions which cause the interchain disulfide linkages connecting the polypeptide chains of the IgG molecule to split apart. At the same time, the reducing conditions must be such that remaining portions of the molecule are substantially unaffected. In particular, it is important to note that if the reducing conditions are too severe, specificity of the antibody to the desired antigen may be lost. The reducing conditions are affected by such factors as the reducing agent itself, the pH of the system, the concentration of the reactants and the time of the exposure to the reducing conditions.
It will be appreciated that any chemical procedure which has as its end purpose the modification of an antibody protein structure without altering the antibody activity and specificity of the protein molecule must be carried out with extreme care. It is for this reason that the method of the present invention calls for removing any complete antibody fraction from the serum prior to submitting the serum solution to the reducing conditions. Any IgM molecule remaining in the solution will be reduced by the recommended procedure and, as a result, its acitivty and specificity adversely influenced.
Compositions produced according to the method of the present invention possess agglutinating activity previously attained only by the use of a high protein diluent containing certain macromolecular substances to accelerate agglutination. The modified IgG immunoglobulin molecules behave substantially as
IgM molecules in their agglutinating activity.
Thus, the agglutinating quality of a specific anti-serum may be made to significantly increase. Because no high protein diluent or other macromolecular substance is necessary to attain the desired agglutinating activity, the composite serums of the invention do not enhace spontaneous agglutination of immunoglobulin-coated red blood cells (as commonly found in certain disease states). Moreover, they have the advantage over reagents prepared from serums containing only native IgM antibodies in that they give macroscopic agglutination of antigen-positive cells without extended incubation.
The method of the present invention is applicable to anti-serums to many human blood group antigens. In particular, blood grouping serums have been produced specific to the Rh antigens D, C, E, c, e, CD, DE and
CDE, and to such other blood group antigens as Kell, Fya and S.
According to the method of the present invention, blood grouping serum capable of producing direct agglutination of human erythrocytes in saline solution are produced.
Direct hemagglutination is practical with the compositions of the present invention.
The compositions of the present invention may be prepared from the serum of a single donor known to possess a specific antibody, or may be produced from pooled serum from several donors. Concentration of IgG molecules in the serum may be determined by known procedures, for example, as by single radial immunodiffusion. The IgG fraction and the IgM fraction are first separated. This also can be done by procedures which are routinely followed in the art and typically calls for a partial delipidation by centrifugation after a procedure to precipitate the heavier molecule fraction. In one procedure fractionation and precipitation may be carried out by treating the serum with ammonium sulfate, followed by anion-exchange chromatography on Whatman DE-52 cellulose. In another procedure, the raw serum is placed in a dialysis tubing which, in turn, is submerged in an excess of deionized water. Dialysis causes the salinity of the serum to decrease to the point where the
IgM molecule is no longer soluble. Centrifugation carried out after that point will enable the separation of the precipitated IgM from the soluble IgG.
The Reducing Agent
Any of the milder reducing agents known to be capable of cleaving the S-S bond in polypeptide molecules without having a strong affinity for other bonds and interchain linkages may be utilized. Examples of suitable reducing agents are 2-mercaptoethanol, cysteine, dithiothreitol (DTT, also known as Cleland's Reagent), dithioerythritol (DTE) and mercaptoethylamine. Applicants prefer to use
DDT because it has demonstrated less of a tendency to "over-reduce" and therefore lends itself more readily to a controlled mild reduction.
Concentration
Generally speaking, the acceptable concentration range of the reducing agent will depend upon the nature of the reducing agent and, to some extent, the particular nature of the IgG molecule to be reduced. At all times, the critical determinant will be the creation of controlled reducing conditions which will produce the desired cleavage without affecting the activity or the specificity of the antibody.
For both DTT and DTE, a concentration within the range of 0.5 to 1.0 grams per liter has been found quite acceptable.
To avoid modifying the specificity of the antibody with any of the mentioned reducing agents, it has been found that strict attention must be paid to maintaining an appropriate pH level in the solution. The preferred range for the pH I will be between about 7.8 and about 8.3. The use of a buffer is recommended to stabilize the pH within this range.
A particularly recommended buffer is that known to the art as Tris, which is a commercially available combination of tris(hydroxymethyl)aminomethane hydrochloride and tris(hydroxymethyl)aminomethane.
Reaction Time
One important factor in the development of suitable mild reducing conditions involves the manner and time of exposure of the solution to the reducing agent. Generally speaking, the lower the concentration, the longer the time of exposure necessary to accomplish the desired cleavage. If the reducing agent is added directly to the solution, the solution should be promptly stirred and thereafter allowed to stand at room temperature for the appropriate period of time. Alternatively, higher concentrations of the reducing agent may be added slowly to the solution with constant stirring and/or constant bubbling of nitrogen through the solution. It has also been found acceptable to dialyze the solution against a larger volume of a solution containing the reducing agent.
With reference now to Figs. 1 and 2 of the drawings, there is illustrated a diagrammatic representation of the hypothetical extreme in segmental flexibility in an IgG antibody before (Fig. 1) and after (Fig. 2)mild reduction. The antibody molecule represented is shown to contain two disulfide linkages (which would typically be CYS 226 and CYS 229). The antigen-binding regions of the molecule are indicated as Fab (antigen-binding fragment), each of which is connected through a flexible "hinge" disulfide linkage to an Fc (crystalline) fragment. the crystalline fragment is, in turn, comprised of two distinct domains approximatley equal in size and shape. The two lower domains are shown connected at line 2-2' to form a strongly interacting dimer which has been demonstrated to remain unchanged by mild reduction.The upper domains of the crystalline fragment are glycosylated peptides and therefore do not strongly interact. they are shown connected through the double disu Ifide linkage which is cleaved readily upon mild reduction along the line 1-1'. Apparently, the remaining bonds permit sufficient flexibility after mild reduction to allow the Fab regions and the upper domains of the crystalline fragments to assume the positions shown in Fig. 2.
Note that the interchain disulfide bonds have been chemically reduced to form sulfhydril groups, each sulfur atom having combined with hydrogen. This reaction, however, is readily reversible, occurring almost immediately upon dialysis, for example. Accordingly, following the mild reduction, the modified molecule represented in Fig. 2 must be "fixed" by replacing the hydrogens of the sufhydril groups with chemical groups which are not readily oxidized. One convenient procedure is referred to in the art as "alkylating" which involves replacing the sulfhydril hydrogen with a lower alkyl group. The preferred alkylation agent is either iodoacetic acid or iodoacetamide. It will be readily appreciated that any reagent which effectively prevents reformation of the disulfide bond without altering the antibody activity or specificity will accomplish the desired end result.
The following Examples illustrate the invention.
Example 1-3
The procedure of the present invention was used to reduce several "incomplete" anti-D preparations in an attempt to produce a modified antibody which would yield direct agglutination of D-positive red blood cells in a saline solution.
A pool of 1 50 milliliters of anti-D serum was obtained and divided into three separate, roughly equal portions. These were treated as follows:
1. 40 ml. of the raw serum was dialyzed in a 35 mm. dialysis tubing for seven hours at room temperature against two liters of deionized water. After seven hours, the serum showed a volume of 46 ml. and was slightly turbid. This volume was centrifuged for thirty minutes at 2,000 rpm in order to precipitate insoluble material, which was then removed and re-dissolved in saline. The remaining serum from the dialysis, now at a volume of slightly under 46 ml., was mixed with an equal volume of a 0.01 M. solution of DTT (dithiothreitol) in a tris (hydroxymethyl)aminomethane buffer (0.1 M.) at pH 8.2. This mixture was allowed to stand at room temperature for one hour.Thereafter, 0.425 g. of crystalline iodoacetamide was added, to a final concentration of 25mM. The mixture was then stirred briefly to dissolve the iodoacetamide and thereafter permitted to stand in the dark for one hour. After this, the solution was transferred to a 35 mm. dialysis casing and dialyzed over night at room temperature in the presence of a large excess of 0.05 M Tris buffer at pH 7.8 and 0.15 M NaCI. 86 ml. of solution was recovered. To this was added the saline solution obtained by dissolving the precipitate from the first dialysis step. The anti-D activity to D-positive red cells in saline of the solution had increased substantially over the activity as measured prior to the treatment.
2. A second portion comprising 50 ml. of the serum pool was mixed with 50 ml. of 0.01 M. DTT in a 0.1 M. Tris at pH 8.2. The mixture was allowed to stand at room temperature for one hour after which 0.462 g. of crystalline iodoacetamide was added and dissolved by constant stirring. This solution, in turn, was left standing for one hour at room temperature and then transferred to a 35 mm.
dialysis casing and dialyzed overnight at room temperature against 3.5 liters of a buffer solution consisting of 0.15 M. NaCI and 0.05
M. Tris at a pH 7.8. The recovered volume of 94 ml. was tested to demonstrate a hemagglutinating activity equivalent to an IgM titer significantly higher.
3. The final 50 ml. portion of the serum pool was mixed with 50 ml. potassium phosphate buffer (ionic strength = 0.1) at pH 7.0.
While stirring at room temperature, 43 ml. of a 50% polyethylene glycol 4000 solution was added to bring the PEG concentration to 15%. The resultant mixture was stirred for thirty minutes, during which time a precipitate formed. This was-collected by centrifugation as in Example 1 above. The precipitate was then re-dissolved in 50 ml. of 0.15 M NaCI solution. The supernatant solution was dialyzed against 3.5 liters 0.15 M NaCI solution at room temperature. After dialysis overnight the solution was centrifuged to remove the small amount of insoluble material and had a final volume of about 55 ml. A biuret protein determination showed the solution to contain approximately 1 5 mg. protein/ml. To 50 ml.
of this solution was added 77.2 mg. solid crystalline DTT, producing a DTT concentration equal to 10 mM. After stirring to assure complete solution, the mixture was allowed to stand for one hour at room temperature.
Thereafter, 0.231 g. of solid iodoacetamide was added and after dissolution, the mixture allowed to remain undisturbed at room temperature for one hour. The reduced, alkylated protein was then transferred to dialysis casing and dialyzed overnight against 0.1 5 M NaCI solution buffered to 7.8 with 0.05M Tris. 46 ml. of solution was recovered, which solution demonstrated an appreciable anti-D activity in saline direct agglutination test.
Following the procedures outlined above, reduced and modified IgG antibodies have been produced which are specific to blood group antigens D, C, E, c, e, CD, DE, CDE,
Kell, Fya and S. Moreover, the process of the present invention lends itself readily to the production of acceptable anti-serums specific to any of the blood group antigens.
Claims (9)
1. A method of producing an anti-serum, which comprises (a) removing IgM immunoglobulin fraction from a serum containing IgG immunoglobulin in solution; (b) subjecting the thus-treated solution, containing IgG, to reducing conditions sufficient to split the disu Ifide bonds linking the polypeptide chains of the IgG, substantially without reducing other portions of the IgG; (c) fixing the reduced IgG, thereby substantially preventing reoxidation and reformation of the disulfide bonds; (d) removing any reducing and fixing agents from the solution; and (e) combining the solution with the IgM fraction removed in step (a).
2. A method according to claim 1 wherein the IgM fraction removed in step (a) is dissolved in buffered saline.
3. A method according to claim 1 or claim 2 wherein step (b) comprises dissolving a reducing agent in the solution and maintaining the pH of the solution.
4. A method according to claim 3 wherein the reducing agent is 2-mercaptoethanol, cysteine, dithiothreitol, dithioerythritoi or mercaptoethylamine.
5. A method according to y preceding claim wherein step (c) comprises contacting the solution with an agent capable of alkylating the sulfhydryl group.
6. A method according to claim 5 wherein the alkylating agent is iodoacetic acid or iodoacetamide.
7. A method according to any preceding claim wherein step (d) comprises dialysis.
8. A method according to claim 1 substantially as described in any of the Examples.
9. The agglutination product of human erythrocytes bearing the appropriate specific blood group antigen, in saline solution, with an antibody serum produced by a method according to any preceding claim.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10749979A | 1979-12-26 | 1979-12-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2066259A true GB2066259A (en) | 1981-07-08 |
GB2066259B GB2066259B (en) | 1983-05-25 |
Family
ID=22316939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8023481A Expired GB2066259B (en) | 1979-12-26 | 1980-07-17 | Antibody serum |
Country Status (7)
Country | Link |
---|---|
JP (1) | JPS5694267A (en) |
AU (1) | AU6071780A (en) |
DE (1) | DE3028977A1 (en) |
ES (1) | ES495177A0 (en) |
GB (1) | GB2066259B (en) |
IT (1) | IT8049473A0 (en) |
NZ (1) | NZ194363A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003492A1 (en) * | 1989-09-01 | 1991-03-21 | Central Blood Laboratories Authority | MODIFIED HUMAN ANTI-Rh(D) ANTIBODIES |
WO2005052567A1 (en) * | 2003-11-24 | 2005-06-09 | Biogen Idec Ma Inc. | Methods for detecting half-antibodies using chip-based gel electrophoresis |
AU2002359796B2 (en) * | 2001-12-19 | 2007-07-05 | Biogen Ma Inc. | Methods for detecting half-antibodies using chip-based gel electrophoresis |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61213673A (en) * | 1985-03-19 | 1986-09-22 | Morinaga Milk Ind Co Ltd | Production of reagent for immunological measurement |
CA2008213A1 (en) * | 1989-02-21 | 1990-08-21 | David A. Hilborn | Method of fragmenting certain monoclonal antibodies |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5417721B2 (en) * | 1974-03-08 | 1979-07-02 | ||
ZA804197B (en) * | 1979-07-13 | 1982-02-24 | Ortho Diagnostics | Anti-d test and reagent |
-
1980
- 1980-07-16 NZ NZ194363A patent/NZ194363A/en unknown
- 1980-07-17 GB GB8023481A patent/GB2066259B/en not_active Expired
- 1980-07-23 AU AU60717/80A patent/AU6071780A/en not_active Abandoned
- 1980-07-30 DE DE19803028977 patent/DE3028977A1/en not_active Withdrawn
- 1980-07-30 JP JP10494980A patent/JPS5694267A/en active Pending
- 1980-08-12 IT IT8049473A patent/IT8049473A0/en unknown
- 1980-09-19 ES ES495177A patent/ES495177A0/en active Granted
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003492A1 (en) * | 1989-09-01 | 1991-03-21 | Central Blood Laboratories Authority | MODIFIED HUMAN ANTI-Rh(D) ANTIBODIES |
AU2002359796B2 (en) * | 2001-12-19 | 2007-07-05 | Biogen Ma Inc. | Methods for detecting half-antibodies using chip-based gel electrophoresis |
WO2005052567A1 (en) * | 2003-11-24 | 2005-06-09 | Biogen Idec Ma Inc. | Methods for detecting half-antibodies using chip-based gel electrophoresis |
Also Published As
Publication number | Publication date |
---|---|
ES8106834A1 (en) | 1981-09-01 |
NZ194363A (en) | 1982-12-21 |
JPS5694267A (en) | 1981-07-30 |
IT8049473A0 (en) | 1980-08-12 |
AU6071780A (en) | 1981-07-02 |
ES495177A0 (en) | 1981-09-01 |
DE3028977A1 (en) | 1981-07-02 |
GB2066259B (en) | 1983-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marchalonis et al. | Phylogenetic origins of antibody structure: III. Antibodies in the primary immune response of the sea lamprey, Petromyzon marinus | |
Edelman et al. | Studies on structural units of the γ-globulins | |
Tenner et al. | Purification and radiolabeling of human C1q. | |
Lebacq-Verheyden et al. | A possible homologue of mammalian IgA in chicken serum and secretions | |
Gally et al. | Protein-protein interactions among L polypeptide chains of Bence-Jones proteins and human γ-globulins | |
DE3586679T2 (en) | IMMUNOASSAYS FOR DENATURED PROTEIN ANALYTES, IN PARTICULAR HBALC AND MONOCLONAL ANTIBODIES THEREFOR. | |
Hädge et al. | Evolution of low molecular weight immunoglobulins—IV. IgY-like immunoglobulins of birds, reptiles and amphibians, precursors of mammalian IgA | |
EP0407813B1 (en) | Oxidative denaturation of protein analytes | |
Leslie et al. | Phylogeny of Immunoglobulin Structure and Function: VI. 17S, 7.5 S and 5.7 S anti-DNP of the Turtle, Pseudamys Scripta | |
Brandtzaeg | Immunochemical studies on free and bound J chain of human IgA and IgM | |
WO1982000364A1 (en) | Methods of immuno-analysis using monoclonal antibodies | |
Lachmann | The purification of specific antibody as F (ab′) 2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens | |
Grov | Human colostral IgA interacting with staphylococcal protein A | |
IE53059B1 (en) | A method and a kit for the assay of antibodies to soluble antigens | |
EP0013930A1 (en) | Immunogene, antibody for a thymus hormone, labelled thymus hormone and process for the determination of this thymus hormone | |
Akira et al. | Modification of immunoglobulin G using specific reactivity of sugar moiety | |
Mandy et al. | Characterization of allotype A11 in rabbits: a specificity detected by agglutination | |
GB2066259A (en) | Antibody serum | |
CA2067584C (en) | Agglutinant complex as blood typing reagent | |
EP0566205A1 (en) | Method for the elimination of non-specific reactions in immuno-assays | |
Leslie et al. | Structural and antigenic relationships between avian immunoglobulins: II. Properties of papain-and pepsin-digested chicken, pheasant and quail IgG-immunoglobulins | |
Jaquet et al. | The reductive dissociation of rabbit immune globulin in sodium dodecylsulfate | |
Brandtzaeg | Unfolding of human secretory immunoglobulin A | |
Steiner et al. | Mercury derivatives of the Fab and Fc fragments of a human myeloma protein | |
Dorrington et al. | Studies on the conformation of purified human and canine γA-globulins and equine γT-globulin by optical rotatory dispersion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |